Table 2.
Parameter | Control | Metformin | Sitagliptin | DOX | Metformin/DOX | Sitagliptin/DOX |
---|---|---|---|---|---|---|
Myocardial degeneration | 0 ± 0 | 0 ± 0 | 0 ± 0 | 2.00 ± 0.27a | 0.25 ± 0.04b | 0.50 ± 0.03b |
Interstitial inflammation | 0 ± 0 | 0 ± 0 | 0 ± 0 | 2.75 ± 0.32a | 0.50 ± 0.02b | 1.00 ± 0.07ab |
Interstitial hemorrhage | 0 ± 0 | 0 ± 0 | 0 ± 0 | 2.25 ± 0.21a | 0.75 ± 0.03ab | 0.50 ± 0.02b |
Data were expressed as mean ± SEM of six observations.
aSignificantly different from control group (P < 0.05).
bSignificantly different from doxorubicin group (P < 0.05).